Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease

Johannes Schwarz, A. Antonini, E. Kraft, K. Tatsch, T. Vogl, C. M. Kirsch, K. L. Leenders, W. H. Oertel

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenza-mide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson's disease patients before and 4 months after initiation of D-penicillamine treatment. Before treatment, specific 11C-raclopride binding (only patient 1) was markedly reduced, with a putamen to cerebellum ratio of 1.99 (controls: 3.99 ± 0.55, n = 15) and a caudate to cereb0ellum ratio of 2.52 (controls: 3.65 ± 0.59, n = 15). Specific 123I-IBZM binding was reduced in both patients, with a basal ganglia to frontal cortex ratio of 1.25 (patient 1) and of 1.41 (patient 2) (controls: 1.57 ± 0.04, n = 5). After 4 months of therapy, 11C-raclopride-PET improved to a putamen to cerebellum ratio of 2.52 and a caudate to cerebellum ratio of 3.06(patient 1). 123I-IBZM-SPECT revealed an increase of basal ganglia to frontal cortex ratios of 1.34 (patient 1) and 1.55 (patient 2). On heavily T2-weighted MRI sequences, hyperintense signal changes before therapy within the putamen (both patients), brainstem (only patient 1), and caudate (only patient 2) greatly diminished after treatment. Reduced striatal dopamine D2-receptor binding in these Wilson's disease patients improved under therapy, suggesting, in part, a reversible defect of striatal neurons.

Original languageEnglish
Pages (from-to)1079-1082
Number of pages4
JournalNeurology
Volume44
Issue number6
Publication statusPublished - 1994

Fingerprint

Hepatolenticular Degeneration
Dopamine
Raclopride
Corpus Striatum
Therapeutics
Putamen
Cerebellum
Dopamine D2 Receptors
Frontal Lobe
Basal Ganglia
Single-Photon Emission-Computed Tomography
Penicillamine
Protein Sorting Signals
Brain Stem

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Schwarz, J., Antonini, A., Kraft, E., Tatsch, K., Vogl, T., Kirsch, C. M., ... Oertel, W. H. (1994). Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease. Neurology, 44(6), 1079-1082.

Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease. / Schwarz, Johannes; Antonini, A.; Kraft, E.; Tatsch, K.; Vogl, T.; Kirsch, C. M.; Leenders, K. L.; Oertel, W. H.

In: Neurology, Vol. 44, No. 6, 1994, p. 1079-1082.

Research output: Contribution to journalArticle

Schwarz, J, Antonini, A, Kraft, E, Tatsch, K, Vogl, T, Kirsch, CM, Leenders, KL & Oertel, WH 1994, 'Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease', Neurology, vol. 44, no. 6, pp. 1079-1082.
Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM et al. Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease. Neurology. 1994;44(6):1079-1082.
Schwarz, Johannes ; Antonini, A. ; Kraft, E. ; Tatsch, K. ; Vogl, T. ; Kirsch, C. M. ; Leenders, K. L. ; Oertel, W. H. / Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease. In: Neurology. 1994 ; Vol. 44, No. 6. pp. 1079-1082.
@article{3a2426272d364fe8aec1c521ecac56a2,
title = "Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease",
abstract = "We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenza-mide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson's disease patients before and 4 months after initiation of D-penicillamine treatment. Before treatment, specific 11C-raclopride binding (only patient 1) was markedly reduced, with a putamen to cerebellum ratio of 1.99 (controls: 3.99 ± 0.55, n = 15) and a caudate to cereb0ellum ratio of 2.52 (controls: 3.65 ± 0.59, n = 15). Specific 123I-IBZM binding was reduced in both patients, with a basal ganglia to frontal cortex ratio of 1.25 (patient 1) and of 1.41 (patient 2) (controls: 1.57 ± 0.04, n = 5). After 4 months of therapy, 11C-raclopride-PET improved to a putamen to cerebellum ratio of 2.52 and a caudate to cerebellum ratio of 3.06(patient 1). 123I-IBZM-SPECT revealed an increase of basal ganglia to frontal cortex ratios of 1.34 (patient 1) and 1.55 (patient 2). On heavily T2-weighted MRI sequences, hyperintense signal changes before therapy within the putamen (both patients), brainstem (only patient 1), and caudate (only patient 2) greatly diminished after treatment. Reduced striatal dopamine D2-receptor binding in these Wilson's disease patients improved under therapy, suggesting, in part, a reversible defect of striatal neurons.",
author = "Johannes Schwarz and A. Antonini and E. Kraft and K. Tatsch and T. Vogl and Kirsch, {C. M.} and Leenders, {K. L.} and Oertel, {W. H.}",
year = "1994",
language = "English",
volume = "44",
pages = "1079--1082",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Treatment with d–penicillamine improves dopamine D2–receptor binding and T2–signal intensity in de novo wilson's disease

AU - Schwarz, Johannes

AU - Antonini, A.

AU - Kraft, E.

AU - Tatsch, K.

AU - Vogl, T.

AU - Kirsch, C. M.

AU - Leenders, K. L.

AU - Oertel, W. H.

PY - 1994

Y1 - 1994

N2 - We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenza-mide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson's disease patients before and 4 months after initiation of D-penicillamine treatment. Before treatment, specific 11C-raclopride binding (only patient 1) was markedly reduced, with a putamen to cerebellum ratio of 1.99 (controls: 3.99 ± 0.55, n = 15) and a caudate to cereb0ellum ratio of 2.52 (controls: 3.65 ± 0.59, n = 15). Specific 123I-IBZM binding was reduced in both patients, with a basal ganglia to frontal cortex ratio of 1.25 (patient 1) and of 1.41 (patient 2) (controls: 1.57 ± 0.04, n = 5). After 4 months of therapy, 11C-raclopride-PET improved to a putamen to cerebellum ratio of 2.52 and a caudate to cerebellum ratio of 3.06(patient 1). 123I-IBZM-SPECT revealed an increase of basal ganglia to frontal cortex ratios of 1.34 (patient 1) and 1.55 (patient 2). On heavily T2-weighted MRI sequences, hyperintense signal changes before therapy within the putamen (both patients), brainstem (only patient 1), and caudate (only patient 2) greatly diminished after treatment. Reduced striatal dopamine D2-receptor binding in these Wilson's disease patients improved under therapy, suggesting, in part, a reversible defect of striatal neurons.

AB - We report the results of in vivo striatal dopamine D2-receptor binding assessed by PET using 11C-raclopride (only one patient) and by single-photon emission computed tomography (SPECT) using 123I-iodobenza-mide (123I-IBZM) and the findings of T2-weighted MRIs in two de novo Wilson's disease patients before and 4 months after initiation of D-penicillamine treatment. Before treatment, specific 11C-raclopride binding (only patient 1) was markedly reduced, with a putamen to cerebellum ratio of 1.99 (controls: 3.99 ± 0.55, n = 15) and a caudate to cereb0ellum ratio of 2.52 (controls: 3.65 ± 0.59, n = 15). Specific 123I-IBZM binding was reduced in both patients, with a basal ganglia to frontal cortex ratio of 1.25 (patient 1) and of 1.41 (patient 2) (controls: 1.57 ± 0.04, n = 5). After 4 months of therapy, 11C-raclopride-PET improved to a putamen to cerebellum ratio of 2.52 and a caudate to cerebellum ratio of 3.06(patient 1). 123I-IBZM-SPECT revealed an increase of basal ganglia to frontal cortex ratios of 1.34 (patient 1) and 1.55 (patient 2). On heavily T2-weighted MRI sequences, hyperintense signal changes before therapy within the putamen (both patients), brainstem (only patient 1), and caudate (only patient 2) greatly diminished after treatment. Reduced striatal dopamine D2-receptor binding in these Wilson's disease patients improved under therapy, suggesting, in part, a reversible defect of striatal neurons.

UR - http://www.scopus.com/inward/record.url?scp=0028308583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028308583&partnerID=8YFLogxK

M3 - Article

C2 - 8208404

AN - SCOPUS:0028308583

VL - 44

SP - 1079

EP - 1082

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -